比较两项帕金森病脑深部电刺激随机试验
该研究比较了德国LQ研究和美国VA/NINDS试验中接受丘脑底核DBS的患者,发现两项研究基线人口学特征和左旋多巴反应性存在显著差异。校正左旋多巴反应性后,两组运动功能改善无显著差异,提示患者选择标准尤其是术前左旋多巴反应性是结局差异的主要来源。
要点
- 两项随机试验的DBS运动结局差异主要源于术前左旋多巴反应性不同。
- 左旋多巴完全反应者中,LQ与VA/NINDS的UPDRS-III改善无显著差异。
- 患者选择标准对DBS临床试验结局比较至关重要。
核心结论
- 患者选择标准,尤其是术前左旋多巴反应性,是两项研究运动结局和生活质量差异的最重要来源。
研究设计与样本
- 比较德国帕金森病能力网络生活质量研究(LQ研究)与美国退伍军人事务部/国立神经疾病与卒中研究所试验(VA/NINDS试验)的随机对照试验数据。
- 分析基于接受DBS植入且有可用数据的受试者(LQ研究76例,VA/NINDS试验140例;完成者LQ 69例,VA/NINDS 125例)。
- 使用两项研究6个月随访数据,因为这是LQ研究的终点。
主要发现
- DBS前基线人口学特征在两项研究间存在显著差异,包括LQ研究人群的左旋多巴反应性高于VA/NINDS组。
- DBS后LQ受试者在运动功能(UPDRS-III)、日常生活活动能力和治疗并发症方面改善更大。
- 药物减少和非日常生活活动的生活质量改善在LQ与VA/NINDS受试者间无显著差异。
- 左旋多巴完全反应者(用药后UPDRS-III改善≥50%)中,DBS运动改善无显著差异(LQ改善18.5±12.0分 vs VA/NINDS改善17.7±15.6分,p=0.755)。
- 左旋多巴完全反应者中,LQ组日常生活活动能力改善略多,但其他UPDRS子量表和帕金森病问卷-39评分无显著差异。
关键数值与推荐
- 左旋多巴完全反应者定义为用药后UPDRS-III改善≥50%。
临床怎么用
- 在比较DBS研究结局或选择患者时,应充分考虑术前左旋多巴反应性等选择标准的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Several randomized studies have compared the effect of deep brain stimulation (DBS) of the subthalamic nucleus with the best medical treatment in large groups of patients. Important outcome measures differ between studies. Two such major studies, the life-quality study of the German Competence Network for Parkinson's disease (LQ study) and the US Veterans Affairs/National Institute of Neurological Disorders and Stroke trial (VA/NINDS trial), were compared here in order to understand their differences in outcomes. METHODS: Unless otherwise noted, analyses were based on those subjects in each study who received a DBS implant (LQ study 76 patients, VA/NINDS trial 140 patients) and who had data for the measurement under consideration (i.e., no imputations for missing data), referred to hereafter as the "as-treated completers" (LQ 69 patients, VA/NINDS 125 patients). Data were prepared and analyzed by biostatisticians at the US Department of Veterans Affairs Cooperative Studies Program Coordinating Center, the Coordinating Center for Clinical Trials Marburg, and Medtronic, under the direction of two authors (G.D. and K.A.F.). Data were extracted from the respective databases into SAS data sets and analyzed using SAS software. Analyses were based on the 6-month follow-up data from both studies because this was the endpoint for the LQ study. RESULTS: Pre-DBS baseline demographics differed significantly between the studies, including greater levodopa responsiveness (LDR) in the LQ study population than in the VA/NINDS group. After DBS, LQ subjects demonstrated greater improvement in motor function (Unified Parkinson's Disease Rating Scale, Motor Examination [UPDRS-III]), activities of daily living (ADLs), and complications of therapy. Medication reduction and improvements in life quality other than ADLs were not significantly different between LQ and VA/NINDS subjects. When the two populations were compared according to pre-DBS LDR, the "full responders" to levodopa (≥ 50% improvement on UPDRS-III with medication) in the two studies showed no significant difference in motor improvement with DBS (LQ 18.5 ± 12.0-point improvement on UPDRS-III vs VA/NINDS 17.7 ± 15.6-point improvement, p = 0.755). Among levodopa full responders, ADLs improved slightly more in the LQ group, but scores on other UPDRS subscales and the Parkinson's Disease Questionnaire-39 were not significantly different between the two studies. CONCLUSIONS: This comparison suggests that patient selection criteria, especially preoperative LDR, are the most important source of differences in motor outcomes and quality of life between the two studies.
引用
- Deuschl G, Follett KA, Luo P, et al. Comparing two randomized deep brain stimulation trials for Parkinson's disease. J Neurosurg. 2019. PMID: 30952118. doi:10.3171/2018.12.JNS182042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。